BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- Biological: Placebo matching IpilimumabBiological: Ipilimumab
- First Posted Date
- 2011-10-12
- Last Posted Date
- 2020-07-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1351
- Registration Number
- NCT01450761
- Locations
- 🇺🇸
University Of Texas, M. D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸University Hospitals, Cleveland, Ohio, United States
🇺🇸Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States
Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C
- Conditions
- Hepatitis C
- Interventions
- First Posted Date
- 2011-10-07
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 152
- Registration Number
- NCT01448044
- Locations
- 🇺🇸
University Gastroenterology, Providence, Rhode Island, United States
🇺🇸Metropolitan Research, Annandale, Virginia, United States
🇬🇧Local Institution, London, Greater London, United Kingdom
Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C
- Conditions
- Hepatitis C Virus (HCV)
- Interventions
- First Posted Date
- 2011-10-06
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT01447394
- Locations
- 🇬🇧
Local Institution, Birmingham, West Midlands, United Kingdom
Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects
- Conditions
- Hepatitis C
- Interventions
- Drug: 100 mg INX-08189 BID FastedDrug: 100 mg INX-08189 QDDrug: 100 mg INX-08189 with low-fat mealDrug: 200 mg INX-08189 FastedDrug: Placebo QD FastedDrug: Placebo QDDrug: Placebo with low-fat mealDrug: Placebo BID Fasted
- First Posted Date
- 2011-10-04
- Last Posted Date
- 2016-06-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 50
- Registration Number
- NCT01445795
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
- Conditions
- Smoldering Multiple Myeloma
- Interventions
- Biological: Elotuzumab (BMS-901608; HuLuc63)
- First Posted Date
- 2011-09-28
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 41
- Registration Number
- NCT01441973
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸Sharp Clinical Oncology Research, San Diego, California, United States
🇺🇸Winship Cancer Institute., Atlanta, Georgia, United States
Pharmacokinetic Study to Compare the Blood Levels of Abatacept Manufactured at Lonza Biologics to the Blood Levels of Abatacept Manufactured at the Devens, Massachusetts (MA) Facility of Bristol-Myers Squibb
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: Abatacept (BMS-188667)
- First Posted Date
- 2011-09-23
- Last Posted Date
- 2014-03-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 223
- Registration Number
- NCT01439204
- Locations
- 🇺🇸
Icon Clinical Pharmacology Unit, Llc, Omaha, Nebraska, United States
Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials
- First Posted Date
- 2011-09-22
- Last Posted Date
- 2012-08-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1053
- Registration Number
- NCT01438424
Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis
- First Posted Date
- 2011-09-21
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 289
- Registration Number
- NCT01437787
- Locations
- 🇺🇸
Investigational Site Number 840013, Baton Rouge, Louisiana, United States
🇺🇸Investigational Site Number 840014, Scottsdale, Arizona, United States
🇮🇱Investigational Site Number 376002, Tel Hashomer, Israel
Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials
- Conditions
- Hepatitis C Virus Infection
- Interventions
- First Posted Date
- 2011-09-02
- Last Posted Date
- 2016-05-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 276
- Registration Number
- NCT01428063
- Locations
- 🇺🇸
Scpmg/ Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸Mercy Medical Center, Baltimore, Maryland, United States
🇺🇸University Of Pennsylvania, Philadelphia, Pennsylvania, United States
Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin
- Conditions
- Hepatitis C
- Interventions
- Drug: Placebo matching with INX-08189Biological: Pegylated interferon alfa-2a
- First Posted Date
- 2011-08-30
- Last Posted Date
- 2015-11-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 210
- Registration Number
- NCT01425970
- Locations
- 🇺🇸
Alamo Medical Research, San Antonio, Texas, United States
🇺🇸Options Health Research, Llc, Tulsa, Oklahoma, United States
🇺🇸Quest Clinical Research, San Francisco, California, United States